Notably, many cholinesterase inhibitors have been approved by the FDA as therapeutic agents for treatment of Alzheimer’s disease (AD), myasthenia gravis, glaucoma, and Parkinson’s disease etc. Most of these cholinesterase inhibitors are able to inhibit both AChE and BChE, without the desirable high selectivity for BChE over AChE. Here, ACHE is linked to myasthenia gravis.